biomarkers in the ed - useful or useless
TRANSCRIPT
![Page 1: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/1.jpg)
Bringing sexy back?
biomarkers - useful or useless?Katrin Hruska
![Page 2: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/2.jpg)
No disclosures
![Page 3: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/3.jpg)
![Page 5: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/5.jpg)
”in the near future, high suPAR levels probably will inform physician-patient conversations about
preventing kidney disease"
![Page 6: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/6.jpg)
”rigorous NEJM study is a significant breakthrough in preventive medicine"
![Page 7: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/7.jpg)
![Page 8: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/8.jpg)
Groundbreaking blood test predicts kidney disease FIVE YEARS BEFORE symptoms appear
![Page 9: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/9.jpg)
”Trisaq's product strategy has been designed to yield early proof-of-
concept as well as commercialization opportunities”
”Conservatively estimated, Trisaq's current pipeline of products can benefit about 15-25% of all CKD patients and their combined sales potential well
exceeds $1 billion.
![Page 10: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/10.jpg)
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
![Page 11: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/11.jpg)
![Page 12: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/12.jpg)
Novel Blood Biomarker May Predict CKD RiskOutcomes studies necessary to prove clinical efficacy
![Page 13: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/13.jpg)
suPAR: Strong and independent predictor of survival
![Page 14: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/14.jpg)
![Page 15: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/15.jpg)
![Page 16: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/16.jpg)
Rather young and healthy than old and
sick
![Page 17: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/17.jpg)
![Page 18: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/18.jpg)
The primary endpoint was to create an accurate prognostication score of death by combining APACHE II score and serum suPAR.
![Page 19: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/19.jpg)
💀14 ng/mL
3-70 ng/mL 1-65 ng/mL
😀9 ng/mL
suPAR levels and survival in sepsis
range:
![Page 20: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/20.jpg)
Copyright ©2012 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd. Crit Care. 2012; 16(4): R149.
![Page 21: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/21.jpg)
suPAR
Copyright ©2012 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd. Crit Care. 2012; 16(4): R149.
![Page 22: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/22.jpg)
APACHE II
![Page 23: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/23.jpg)
Copyright ©2012 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd. Crit Care. 2012; 16(4): R149.
![Page 24: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/24.jpg)
Copyright ©2012 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd. Crit Care. 2012; 16(4): R149.
![Page 25: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/25.jpg)
Mor
talit
y%
0
10
20
30
40
i ii iii iv
Apache II<17 Apache II≥17
suPAR≥12
suPAR≥12
”validated” in a Swedish cohort
![Page 26: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/26.jpg)
Mor
talit
y%
0
10
20
30
40
i ii iii iv
suPAR≥12
suPAR≥12
the high mortality in stratum (ii) may be due to small number of patients in this group (n = 21) and chance variations in mortality. Apart from that
aberration, the findings validate those from the larger Greek study
”validated” in a Swedish cohort
![Page 27: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/27.jpg)
”this strong discriminative prognostic score developed in Greek patients was validated in a cohort of Swedish patients”
”There is no doubt that suPAR has strong prognostic value in ICU patients. However, in many cases this knowledge may not lead to lifesaving interventions, as limited treatment options are efficient
in severely ill sepsis patients”
![Page 28: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/28.jpg)
Prediction of 30 day mortality compared to Danish Emergency Process Triage
![Page 29: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/29.jpg)
![Page 30: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/30.jpg)
Agreement in 55% of cases
”additional biomarkers other than CT are needed"
”we acknowledge the editorial and statistical contribution of Leslie S. Prichep, PhD”
![Page 31: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/31.jpg)
”we acknowledge the editorial and statistical contribution of Leslie S. Prichep, PhD”
![Page 32: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/32.jpg)
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention
![Page 33: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/33.jpg)
A clinical endpoint is a characteristic or variable that reflects how a patient feels, functions or survives
A surrogate endpoint is a biomarker that is intended to substitute for a clinical endpoint
![Page 34: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/34.jpg)
A clinical endpoint is a characteristic or variable that reflects how a patient feels, functions or survives
A surrogate endpoint is a biomarker that is intended to substitute for a critical endpoint
![Page 35: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/35.jpg)
Image: Bengt Nyman
SNTF
![Page 36: Biomarkers in the ED - useful or useless](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58859b4a1a28abd2498b5a53/html5/thumbnails/36.jpg)
photo: Michele di Trani
So you think you’re in pain?